Feasibility of lung cancer screening in low-risk populations of the Nordic countries

de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6): 503–13.

https://doi.org/10.1056/NEJMoa1911793 DOI: https://doi.org/10.1056/NEJMoa1911793

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

https://doi.org/10.1056/NEJMoa1102873 DOI: https://doi.org/10.1056/NEJMoa1102873

Pastorino U, Silva M, Sestini S, Fabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30:1162–9.

https://doi.org/10.1093/annonc/mdz117 DOI: https://doi.org/10.1093/annonc/mdz117

Recommendation (CR) on strengthening prevention through early detection: a new approach on cancer screening replacing CR 2003/878/EC [Internet]. 2022. Available from: https://health.ec.europa.eu/publications/proposal-council-recommendation-cr-strengthening-prevention-through-early-detection-new-approach_en

Henschke C, Huber R, Jiang L, Yang D, Cavic M, Schmidt H, et al. Perspective on management of low-dose computed tomography findings on low-dose computed tomography examinations for lung cancer screening. From the International Association for the Study of Lung Cancer Early Detection and Screening Committee. J Thorac Oncol. 2024;19(4):565–80.

https://doi.org/10.1016/j.jtho.2023.11.013 DOI: https://doi.org/10.1016/j.jtho.2023.11.013

Holst Pedersen J, Sorensen JB, Saghur Z, Flotten O, Brustuun OT, Ashraf H, et al. Implementation of lung cancer CT screening in the Nordic countries. Acta Oncol. 2017;56(10):1249–57.

https://doi.org/10.1080/0284186X.2017.1329592 DOI: https://doi.org/10.1080/0284186X.2017.1329592

Pinsky PF. Assessing the benefits and harms of low-dose computed tomography screening for lung cancer. Lung Cancer Manag. 2014;3(6):491–8.

https://doi.org/10.2217/lmt.14.41 DOI: https://doi.org/10.2217/lmt.14.41

Del Pilar Fernandez Montejo M, Saghir Z, Bodtger U, Jepsen R, Lynge E, Loåjhaven S. Identifying the population to be targeted in a lung cancer screening programme in Denmark. BMJ Open Respir Res. 2024;11(1):e002499.

https://doi.org/10.1136/bmjresp-2024-002499 DOI: https://doi.org/10.1136/bmjresp-2024-002499

Grundberg O, Kalinowska P, Hillegren P, Janvid NP, Dimberg A, Markholm Nordgren N, et al. The Stockholm Pilot study for lung ­cancer screening (StockholmPLUS): feasibility of low-dose CT lung cancer screening in a high-risk Swedish female population. Acta Oncol. 2026;65:164–72.

https://doi.org/10.2340/1651-226X.2026.44826 DOI: https://doi.org/10.2340/1651-226X.2026.44826

Mahovkic A, Neumann K, Strand T-E, Roe OD, Ashraf H. Baseline results from the Norwegian lung cancer screening trial. Acta Oncol. 2026;65:59–65.

https://doi.org/10.2340/1651-226X.2026.44910 DOI: https://doi.org/10.2340/1651-226X.2026.44910

Ilvanainen S, Kurtti A, Wichmann V, Andersen H, Jekunen H, Kaarteenaho R, et al. Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial. Lancet Reg Health Eur 2024;42:100946.

https://doi.org/10.1016/j.lanepe.2024.100946 DOI: https://doi.org/10.1016/j.lanepe.2024.100946

Wichmann V, Iivanainen S, Mattila L, Kokkonen V-P, Jartti A, Kurtti A, et al. Lung cancer screening in Finland: a prospective randomized trial. Acta Oncol. 2025;64:769–74.

https://doi.org/10.2340/1651-226X.2025.43093 DOI: https://doi.org/10.2340/1651-226X.2025.43093

van der Aalst CM, Ten Haaf K, de Koning HJ. Implementation of lung cancer screening: what are the main issues? Transl Lung Cancer Res. 2021;10(2):1050–63.

https://doi.org/10.21037/tlcr-20-985 DOI: https://doi.org/10.21037/tlcr-20-985

Kauczor H-U, Bonomo L, Gaga M. Lung cancer screening white paper: a slippery step forward? Eur Respir J. 2015;46(5):1521–2.

https://doi.org/10.1183/13993003.01103-2015 DOI: https://doi.org/10.1183/13993003.01103-2015

Hvitfeldt Fuglsang C, Trolle Andersen I, Bredahl Kristensen FP, Engberg H, Borg M, Hilberg O, et al. Pulmonary nodules in Denmark: occurrence, resource use, and risk of lung cancer and death. Acta Oncol. 2025;64:1497–505.

https://doi.org/10.2340/1651-226X.2025.44711 DOI: https://doi.org/10.2340/1651-226X.2025.44711

Baldwin DR, O’Dowd EL, Tietzova I. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard. Eur Respir J. 2023;61(6):2300128.

https://doi.org/10.1183/13993003.00128-2023 DOI: https://doi.org/10.1183/13993003.00128-2023

Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, et al. Lung Screen Uptake Trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med. 2020;201(8):965–75.

https://doi.org/10.1164/rccm.201905-0946OC DOI: https://doi.org/10.1164/rccm.201905-0946OC

Nguyen OTD, Fotopoulos I, Markaki M, Tsamardinos I, Lagani V, Røe OD. Improving lung cancer screening selection: the HUNT lung cancer risk model for ever-smokers versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: a population-based prospective study. JTO Clin Res Rep. 2024;5(4):100660.

https://doi.org/10.1016/j.jtocrr.2024.100660 DOI: https://doi.org/10.1016/j.jtocrr.2024.100660

Feng X, Goodley P, Alcala K, Guida F, Kaaks R, Vermeulen R, et al. Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis. Lancet Digit Health. 2024;6(9):e614–24.

https://doi.org/10.1016/S2589-7500(24)00123-7 DOI: https://doi.org/10.1016/S2589-7500(24)00123-7

Borg M, Neumann K, Frolund JC, Khalife G, Saghir Z, Knuuttila A, et al. Current opinions on lung cancer screening in the Nordic countries: a survey-based study. J Cancer Policy. 2026;47:100703.

https://doi.org/10.1016/j.jcpo.2026.100703 DOI: https://doi.org/10.1016/j.jcpo.2026.100703

Cinciripini PM, Minnix JA, Kypriotakis G, Erasmus J, Beneventi D, Karam-Hage M, et al. Smoking cessation interventions in the lung cancer screening setting: a randomized clinical trial. JAMA Intern Med. 2025;185(3):284–91.

https://doi.org/10.1001/jamainternmed.2024.7288 DOI: https://doi.org/10.1001/jamainternmed.2024.7288

Williams PJ, Philip KE, Alghamdi SM, Perkins AM, Buttery SC, Polkey MI, et al. Strategies to deliver smoking cessation interventions during targeted lung health screening – a systematic review and meta-analysis. Chron Respir Dis. 2023;20:14799731231183446.

https://doi.org/10.1177/14799731231183446 DOI: https://doi.org/10.1177/14799731231183446

Boeri M, Sabia F, Ledda RD, Balbi M, Suatoni P, Segale M, et al. Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial. Lancet Reg Health Eur. 2024;46:101070.

https://doi.org/10.1016/j.lanepe.2024.101070 DOI: https://doi.org/10.1016/j.lanepe.2024.101070

Mohamed E, García Martínez DJ, Hosseini M-S, Yoong SQ, Fletcher D, Hart S, et al. Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis. 2024;45(1–2):1–22.

https://doi.org/10.1093/carcin/bgad091 DOI: https://doi.org/10.1093/carcin/bgad091